Jefferies sees 34% upside in Dormakaba on margin expansion, U.S. growth

Jefferies upgraded Dormakaba (SIX: DOKA) to 'buy' with a CHF 82 price target, citing margin expansion and U.S. growth. The target implies 34% upside from the Sept. 25 close. The broker expects adjusted EBITDA margins to rise to 18% by fiscal 2028/29, above consensus. Dormakaba reported a record EBITDA margin of 16.1% in fiscal 2025/26, driven by cost savings and pricing gains. The company's restructuring program delivered CHF 235 million in savings, exceeding its target.

Original reporting
Published Sep 28, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 12:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$DRRKF
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

High
01

Why it matters

The upgrade could trigger buying interest and push the share price toward the new target.

02

Market read

Analyst upgrade with a specific price target offers a clear trading signal for Dormakaba.

03

What to watch

Potential dilution from the ownership‑structure simplification and upcoming AGM vote.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Jefferies' research note provides new valuation and margin guidance for Dormakaba.

Market effects

Positive outlook for the access‑solutions sector as margin expansion may set a benchmark.

U.S. growth expectations could lift other Swiss exporters with North‑America exposure.

Limited to investors tracking European industrial stocks and AI‑related hardware demand.

Counterpoint

Execution risk remains high; U.S. growth may lag, potentially limiting upside.

Key entities

  • Dormakaba Holding AG

    Swiss access‑solutions maker receiving a buy upgrade.

  • Jefferies

    Analyst firm issuing the upgrade and price target.

Related articles

Med

Dormakaba Q1 organic sales up 4% on price increases; outlook confirmed

Dormakaba reported Q1 2026/27 organic sales growth of 4%, driven by price increases and volume growth. Total net sales rose 5.2% to CHF 702.9 million. The company confirmed its full-year outlook, citing resilience amid geopolitical challenges. Three acquisitions were completed in the quarter. CEO Till Reuter highlighted a strong order book in access solutions.

HighAI 8/10

Why is dormakaba stock surging today?

dormakaba (DOKA) stock rose 5.2% to CHF 60.8 after reporting a record adjusted EBITDA margin of 16.1% for FY2026. The company proposed acquiring the Mankel family's 47.5% stake for CHF 2.13B and a sale-and-leaseback deal for its HQ exceeding CHF 80M. The board also proposed a 3.3% dividend increase to CHF 0.95 per share.

$BABAHigh

Alibaba Slides 7% as Wu’s Promise to “Accelerate Further” Runs Into U.S. Chip Curbs

Alibaba's Hong Kong shares fell 7.3% on November 12 after reports that U.S. rules may restrict Chinese firms from renting advanced chips in overseas data centers. The company rents Nvidia chips through Megaspeed International, making it more vulnerable than peers like Tencent. Alibaba's cloud revenue grew 45% last quarter, but CEO Eddie Wu linked future growth to increased supply, which the reported rules could threaten. The company is set to report September-quarter results on November 19.

$NVDAMed

Key facts: NVDA succession report; Q3 forecast; shares fall 4%

NVIDIA (NVDA) reportedly considered Arm CEO Rene Haas as Jensen Huang's successor. The company forecasted $108B revenue for Q3, missing analyst expectations. Shares fell 4% after a resignation announcement. Leadership changes and export limits to China are under discussion. Yorkville Ives lowered its price target to $225. A petition to reinstate Huang surpassed 135,000 signatures.